How much does a bottle of Encidipine cost?

Enasidenib is an oral targeted drug mainly used to treat specific types of acute myeloid leukemia (AML). It is approved to treat patients with relapsed or refractory AML harboring mutations in the IDH2 gene.

Ensidipine is not currently on the market in China, so patients cannot purchase encidipine domestically and need to purchase encidipine through overseas channels. The cheaper ones abroad are generic drugs, especially the Laos version and the Bangladeshi version. The price ranges from more than 2,000 yuan to more than 4,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

IDH2 gene mutation is a common genetic variation in AML, and about 10% to 15% of AML patients carry this mutation. This mutation leads to an increase in the activity of the IDH2 enzyme, thereby promoting the abnormal proliferation and survival of AML cells. By inhibiting the activity of IDH2 enzyme, ensidipine blocks abnormal metabolic pathways and promotes the maturation and apoptosis of AML cells, thereby inhibiting the growth and spread of tumors.

Clinical trials have shown that ensidipine has demonstrated significant anti-tumor activity in the treatment of patients with relapsed or refractory AML harboring IDH2 gene mutations, and produced durable clinical responses in some patients. Therefore, it proved to be an effective treatment option, bringing new hope to this group of patients with AML.

However, ensidipine may also cause some adverse reactions, such as nausea, vomiting, fatigue, diarrhea, etc., as well as some serious adverse events, such as cytokine release syndrome, abnormal liver function, etc. Therefore, when using ensidipine to treat AML, it is necessary to closely monitor the patient's condition and adverse reactions, and take appropriate treatment measures as needed.

To sum up, ensidipine is a drug that targets the IDH2 gene mutation and is used to treat patients with relapsed or refractory AML with this mutation. It provides an effective treatment option for this group of AML patients and brings hope for improving patients' survival and quality of life.